The FDA's Safer Technologies Program (STeP) is a voluntary initiative designed to accelerate the development and clearance of medical devices that have the potential to reduce known risks associated with current treatments for non-life threatening conditions.

Paxman submitted the STeP Designation Request Q240974/S002 in August 2025. Confirmation that the PLCS meets the eligibility factors for STeP is a significant milestone in Paxman’s regulatory pathways towards FDA clearance of this new technology.

Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting toxicity of paclitaxel and docetaxel, which are both widely used drugs for the treatment of common cancers including breast, ovarian, endometrial, lung, and gastric cancers. CIPN is an unseen, debilitating, and lifelong condition that severely impacts the quality of life of cancer patients.

Acceptance into STeP underscores the innovative potential of the Paxman device to address this important unmet clinical need of reducing the incidence and severity of CIPN in cancer patients receiving systemic neurotoxic chemotherapy or combination therapy.

Richard Paxman, CEO comments, “Inclusion in STeP not only highlights the promise of the new Paxman technology but reflects the FDA’s confidence in our commitment to safety, quality, and innovation. We look forward to continued development and regulatory progress as we move toward future submissions, clinical milestones and ultimately commercial availability of the device to help improve the quality of life for cancer patients around the world.”